GFAP and amyloidosis: NLY01, an exendin-4 derivative, administered using doses of 1 or 10 mg/kg starting at the age of 3 months, for a total of 4 months, resulted in improved spatial learning and attenuated hippocampal amyloid plaque burden and GFAP expression in 5XFAD mice [36].